ACAD vs MRK · P/E 15, rev $576.0M vs P/E 33, rev $16.61B
ACADIA Pharmaceuticals Inc (ACAD) versus Merck & Company Inc (MRK) — a side-by-side from cached financials, not a winner call.
ACADIA Pharmaceuticals Inc (ACAD) is a biotechnology company listed on US.
Merck & Company Inc (MRK) is a drug manufacturers - general company listed on NYSE. It is led by Rob Davis.
Latest reported ACAD revenue for 2026-06-30 was $576.0M. Net income was $35.1M. ACAD currently screens at market cap $3.51B and trailing P/E 15.3.
Latest reported MRK revenue for 2026-06-30 was $16.61B. Net income was -$1.33B. Revenue was up 2.0% from 2026-03-31 to 2026-06-30. MRK currently screens at market cap $285.12B and trailing P/E 32.5.
ACAD currently screens at market cap $3.51B and trailing P/E 15.3. MRK currently screens at market cap $285.12B and trailing P/E 32.5.
Not investment advice. Open the ACAD and MRK stock pages for the full models.
Not investment advice.